Note A - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2024	Mar. 01, 2025	Jun. 30, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	158,319	173,230	238,739	215,180
Contract with Customer, Refund Liability	$ 9,000		$ 9,000
Sales, Royalty and Licensing Revenue	1,700,000	$ 2,700,000	6,000,000	$ 6,600,000
Royalty Expense	$ 56,000	$ 96,000	$ 210,000	$ 278,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0	0	0	0
Share-Based Payment Arrangement, Expense	$ 200,000	$ 200,000	$ 800,000		$ 900,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 900,000		$ 900,000	$ 900,000	$ 200,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Net Asset (Liability)	151,000		151,000				$ 590,000
Fair Value, Inputs, Level 2 [Member] | Line of Credit [Member]
Debt Instrument, Fair Value Disclosure	2,000,000		2,000,000				3,400,000
Fair Value, Inputs, Level 2 [Member] | Term Loan [Member]
Debt Instrument, Fair Value Disclosure	9,000,000		9,000,000				9,200,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Net Asset (Liability)	$ 0		$ 0				$ 0
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	24,000	151,500	24,000	166,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)	0	3,000	0	3,000